Logo for Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Investor Relations Material

Latest events

Logo for Supernus Pharmaceuticals Inc

Q3 2023

Supernus Pharmaceuticals
Logo for Supernus Pharmaceuticals

Q3 2023

8 Nov, 2023
Logo for Supernus Pharmaceuticals

R&D Day 2023

18 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its lead product candidate is Duopa (levodopa-carbidopa intestinal gel), a combination of levodopa and carbidopa for the treatment of Parkinson's disease in adults experiencing end-of-dose wearing off and end-of-dose dyskinesia; and ondansetron hydrochloride injectable suspension, which is being developed as a potential next generation form of treatment for chemotherapy-induced nausea and vomiting.